Literature DB >> 20406638

Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.

Qing Wang1, Junqiang Yan, Xiaohong Chen, Jin Li, Yu Yang, Jianping Weng, Chao Deng, Midori A Yenari.   

Abstract

Statins have been widely used for the treatment of a variety of conditions beyond their original role in lowering cholesterol. Since statins have relatively few side effects, they have been recognized as useful medicine to ameliorate neurodegenerative disorders. Current studies on the applications of statins have demonstrated their neuroprotective and clinical significance among neurodegenerative diseases like cerebral ischemic stroke, vascular dementia, Alzheimer's disease, and Parkinson's disease, though the neuroprotective mechanisms are not completely understood. This review will discuss recent development in the use of statins in slowing down the progression of these neurodegenerative diseases. It will summarize the potential mechanisms for statin-mediated neuroprotective effects in neurodegenerative diseases. In detail, this review discuss the roles of statins in lowering cholesterol, reducing reactive oxygen species, impairing β-amyloid production and serum apolipoprotein E levels, enhancing the levels of endothelial nitric oxide synthase and cerebral blood flow, and modulating cognitive related receptors and matrix metalloproteases. Finally, different alterations of various receptors in brain regions following statin treatment and their correlations with cognitive dysfunction in Parkinson's disease will also be reviewed, as well as the potential for therapy in ameliorating the progression of Parkinson's disease. This article is part of a Special Issue entitled "Interaction between repair, disease, & inflammation."
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406638     DOI: 10.1016/j.expneurol.2010.04.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  49 in total

1.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

2.  Statin use and risk of Parkinson's disease: a meta-analysis of observational studies.

Authors:  Krishna Undela; Kapil Gudala; Swathi Malla; Dipika Bansal
Journal:  J Neurol       Date:  2012-07-21       Impact factor: 4.849

3.  Neuroprotective effects of bikaverin on H2O2-induced oxidative stress mediated neuronal damage in SH-SY5Y cell line.

Authors:  D Nirmaladevi; M Venkataramana; S Chandranayaka; A Ramesha; N M Jameel; C Srinivas
Journal:  Cell Mol Neurobiol       Date:  2014-05-22       Impact factor: 5.046

Review 4.  Statins and neuroprotection: basic pharmacology needed.

Authors:  W Gibson Wood; Walter E Mΰller; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-01-29       Impact factor: 5.590

5.  Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.

Authors:  Naiani F Marques; Adalberto A Castro; Gianni Mancini; Fernanda L Rocha; Adair R S Santos; Rui D Prediger; Andreza Fabro De Bem; Carla I Tasca
Journal:  Neurotox Res       Date:  2017-11-21       Impact factor: 3.911

6.  The UPRmt Protects Caenorhabditis elegans from Mitochondrial Dysfunction by Upregulating Specific Enzymes of the Mevalonate Pathway.

Authors:  Olga Oks; Shany Lewin; Irina Langier Goncalves; Amir Sapir
Journal:  Genetics       Date:  2018-03-29       Impact factor: 4.562

7.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

8.  Coenzyme Q10 and spinocerebellar ataxias.

Authors:  Raymond Y Lo; Karla P Figueroa; Stefan M Pulst; Chi-Ying Lin; Susan Perlman; George Wilmot; Christopher Gomez; Jeremy Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah Ying; Theresa Zesiewicz; Khalaf Bushara; Michael Geschwind; Guangbin Xia; S H Subramony; Tetsuo Ashizawa; Sheng-Han Kuo
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 9.  Molecular Mechanisms of Vascular Dementia: What Can Be Learned from Animal Models of Chronic Cerebral Hypoperfusion?

Authors:  Si-Qi Du; Xue-Rui Wang; Ling-Yong Xiao; Jian-Feng Tu; Wen Zhu; Tian He; Cun-Zhi Liu
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

10.  Lovastatin induces neuroprotection by inhibiting inflammatory cytokines in 6-hydroxydopamine treated microglia cells.

Authors:  Jun-Qiang Yan; Jia-Chun Sun; Ming-Ming Zhai; Li-Niu Cheng; Xiao-Li Bai; Cui-Ling Feng
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.